{"organizations": [], "uuid": "ab4e628b9af7bfb2eb23dbd4aaa4a176fef122ae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.financialexpress.com", "main_image": "http://www.financialexpress.com/wp-content/uploads/2015/07/Biocons.jpg", "site_section": "http://www.financialexpress.com/", "section_title": "The Financial Express | India News Today,Latest National News,Stock Market Today,SENSEX NIFTY,NSE BSE India,Finance News,Business News", "url": "http://www.financialexpress.com/article/miscellaneous/biocon-q1-net-jumps-23-pc-to-rs-126-cr/106404", "country": "IE", "title": "Biocon Q1 Net jumps 23 pct to Rs 126 cr", "performance_score": 0, "site": "financialexpress.com", "participants_count": 1, "title_full": "Biocon Q1 Net jumps 23 pct to Rs 126 cr | The Financial Express", "spam_score": 0.0, "site_type": "news", "published": "2015-07-24T06:41:00.000+03:00", "replies_count": 0, "uuid": "ab4e628b9af7bfb2eb23dbd4aaa4a176fef122ae"}, "author": "financialexpress.com", "url": "http://www.financialexpress.com/article/miscellaneous/biocon-q1-net-jumps-23-pc-to-rs-126-cr/106404", "ord_in_thread": 0, "title": "Biocon Q1 Net jumps 23 pct to Rs 126 cr", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Other Articles Study says Syria 'most dangerous' while Iceland 'most peaceful' globally Rahul Gandhi slams Tamil Nadu govt as 'liquor lobby loyalist' Gay couple from U.S. in Thai custody battle over surrogate baby Biotechnology major Biocon today reported 23 per cent growth in consolidated net profit at Rs 126 crore for the quarter ended June 30, 2015, compared to Rs 103 crore in the same quarter of last year.\nThe company’s net sales grew by 15 per cent at Rs 857 crore for the period under review as compared to Rs 742 crore in the year-ago period, Biocon Ltd said in a statement.\n“The strong performance this quarter reflects the overall growth of our business backed by a combination of product sales and monetisation of R&D assets through licensing,” Biocon Chairperson and Managing Director Kiran Mazumdar-Shaw said.\nShe said that during the quarter, the company successfully licensed biosimilar “Trastuzumab” in key emerging markets.\n“Our insulins business was boosted with the launch of insulin Glargine in Mexico and Colombia. Our focus on key brands in branded formulations has begun to translate into a better quality of earnings,” she added.\nFurther, the company said that it has appointed Narendra Chirmule as the Head of R&D. He has taken over from Abhijit Barve, who has moved back to the US for personal reasons.\nThe companty has established a new entity – Biocon Pharma Ltd, to support finished dosage of generic business.\n“Our insulins drug product facility in Malaysia, underwent a cGMP audit by the National Pharmaceutical Control Bureau (NPCB), Malaysia. We expect to receive the formal certification in a few weeks. This will be followed by the initiation of the validation batches for the drug product,” it added.\nShares of the company closed 0.45 per cent down at Rs 458.55 apiece on the BSE.\n 23, 2015 10:41 pm", "external_links": [], "published": "2015-07-24T06:41:00.000+03:00", "crawled": "2015-07-24T00:15:23.328+03:00", "highlightTitle": ""}